About us

Why Biose

Biose Industrie is dedicated to microbiome therapeutics, Live Biotherapeutic Products (LBPs), and next-generation Probiotics (NGPs).

Key Advantages

70+ years of GMP experience
Full DS + DP manufacturing under one roof
Commercial scale, 32,000 L fermentation capacity
US tech-transfer facility for rapid client onboarding
Long-term expertise in anaerobes, multi-strain programs, and LBPs

Company activity

Biose Industrie is the world leading CDMO for microbiome therapeutics and Next Generation Probiotics. Our facilities comprise a center of excellence of 52 000m2 based in Aurillac, France and an applied tech transfer laboratory in Boston, USA. We are capable of taking your laboratory strain from process development and scale-up to the delivery of GMP manufacturing services of both drug substance and drug product at clinical and commercial levels. We also finalize the secondary packaging and labelling of your products for shipment to your clinical trial distributor anywhere in the world. Biose Industrie : A real one-stop CDMO.

Core Values

By embodying these values—commitment, agility, responsibility, and expertise—Biose demonstrates its dedication to advancing healthcare and improving patient outcomes. As we continue to grow and evolve, these values will remain at the core of everything we do, guiding our actions and shaping our future success.

Commitment

At Biose Industrie, Commitment is more than just a word – it’s our guiding principle. We understand the critical role we play in bringing life-saving therapies to patients worldwide. Every member of our team is deeply committed to excellence in everything we do, from developing innovative biopharmaceutical process solutions to delivering exceptional manufacturing services. Our unwavering dedication ensures that we meet and exceed the expectations of our clients and partners, making a meaningful impact on global healthcare.

Agility

In the fast-paced biopharmaceutical industry, agility is paramount. At Biose Industrie, we embrace change as an opportunity for growth and innovation. Our agile approach enables us to quickly adapt to evolving market dynamics, regulatory requirements, and technological advancements. Whether it’s scaling up production to meet increased demand or pivoting our strategies in response to new developments, we remain agile and responsive, ensuring that we stay ahead of the game and deliver value to our clients.

Responsibility

As a trusted partner in the biopharmaceutical supply chain, Biose Industrie recognizes the immense responsibility we have to patients, healthcare providers, and the broader community. We hold ourselves to the highest standards of ethical conduct, environmental stewardship, and social responsibility. Our commitment to responsible manufacturing practices, product quality, and regulatory compliance ensures the safety, effectivness, and reliability of the therapies we help bring to market. We are dedicated to making a positive impact on society and upholding the trust placed in us by our stakeholders.

Expertise

Expertise is the cornerstone of our success at Biose Industrie. With decades of collective experience in the biopharmaceutical industry, our team of experts possesses unparalleled knowledge, skills, and technical know-how. From process development and analytical testing to cGMP manufacturing and regulatory affairs, we leverage our expertise to deliver tailored solutions that meet the unique needs of each client. Our relentless pursuit of excellence drives continuous improvement and innovative solutions, positioning Biose Industrie as the leading CDMO in the biopharmaceutical sector.

Business team

Adrien NIVOLIEZ

Interim CBO

Rishi TRIVEDI

Business development director - US & India

Alexander LEPAGE

Business developement director - Europe & Latam

Richard ELLIS

Global business developement director - CDMO services

Management team

Adrien NIVOLIEZ

CEO

Samuel BRISSEZ

VP process

Emmanuelle BARDET

VP quality & QP

Caroline DAUSSET

VP analytics

Bertrand CLAUX

VP human resources

Paul-Marie CHASSAING

VP finance

Nadine DAOU

VP US operations

Company History

2023

Adrien NIVOLIEZ becomes the Chairman and CEO of BIOSE Industrie and the company continues as the world leading CDMO

350 employees

February 2023

BIOSE Industrie raises a joint investment of €80M by L-GAM and the French State through the French Tech Souveraineté scheme and creates 200 jobs

2021

BIOSE Industrie is granted €5M by the French State as part of the France Relance scheme

September 2020

Creation of new offices in Boston, USA

150 employees

July 2020

With the support of Cathay Capital, BIOSE Industrie invests €40M in its Aurillac plant

January 2020

BIOSE and BIOSE Industrie merge to become BIOSE Industrie

60 employees

2017

Adrien NIVOLIEZ becomes the CEO of BIOSE Industrie

2015

2011

Creation of PROBIONIOV, a subsidiary of LYOCENTRE, with a new commercial department in Clermont-Ferrand and the R&D department in Aurillac

2008

Creation of a Research and Development (R&D) department

2007

Stanislas DESJONQUERES becomes the CEO of LYOCENTRE

2005-2007

Consolidation of the manufacturing facilities at the Aurillac plant

1997

Acquisition of LYOCENTRE by Hubert DESJONQUERES, implementing a policy of commercial and industrial revitalization

1975

Creation of the Aurillac plant

1958-1978

Development of the Saint-Simon plant

1951

Creation of LYOCENTRE